Mandate Vinge advises industrifonden in connection with pharmalink’s capital raising of sek 96 million

October 08, 2013

Industrifonden and the Norwegian investment company, Investinor have invested a combined total of SEK 79 million in Pharmalink, the pharmaceuticals development company. Private investors have also contributed to the total capital raising of SEK 96 million. The funds will be used to further develop Pharmalink’s product portfolio.

Pharmalink is a pharmaceuticals company which improves and further develops existing pharmaceuticals. The company is currently conducting the Nefecon project for the treatment of inflammation of the kidneys and the Busulipo project for treatment prior to bone marrow transplantation.

Industrifonden has been a stakeholder in Pharmalink since 2004. The Norwegian investment company, Investinor is a new stakeholder.

Vinge partner Johan Larsson advised Industrifonden

Jerker Kjellander is a new partner in Skåne

Dispute resolution expert Jerker Kjellander has been elected as a partner in Vinge’s Skåne office.
November 20, 2020

Amendments to the Swedish Competition Act provide extended powers for the Swedish Competition Authority

Early in 2021, the Swedish Competition Act (2008: 579) will be amended in several important respects. The background to the amendments is Directive (EU) 2019/1 of the European Parliament and of the Council, which aims to harmonize the investigative and sanctioning powers of the European competition authorities in their enforcement of the EU competition rules. Undertakings active in Sweden will be affected by the amendments in several ways.
October 12, 2020